Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).

被引：13
|
作者：
Reardon, David A.
De Groot, John Frederick
Colman, Howard
Jordan, Justin T.
Daras, Mariza
Clarke, Jennifer Leigh
Nghiemphu, Phioanh Leia
Gaffey, Sarah C.
Peters, Katherine B.
机构：
[1] Harvard Canc Ctr, Dana Farber Canc Inst, Boston, MA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Hunstman Canc Inst Utah, Salt Lake City, UT USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Univ Calif Los Angeles, Los Angeles, CA USA
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
[9] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2010
引用
收藏
页数：2
相关论文
共 50 条
  • [41] SAFETY AND EFFICACY OF BEVACIZUMAB AND ERLOTINIB FOR RECURRENT GLIOBLASTOMA PATIENTS IN A PHASE II STUDY
    Sathornsumetee, Sith
    Desjardins, Annick
    Vredenburgh, James
    Rich, Jeremy
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2008, 10 (05) : 827 - 827
  • [42] NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Nayak, Lakshmi
    Molinaro, Annette
    Peters, Katherine
    Clarke, Jennifer
    Jordan, Justin
    de Groot, John
    Nghiemphu, Phioanh
    Kaley, Thomas
    Colman, Howard
    McCluskey, Christine
    Gaffey, Sarah
    Smith, Timothy
    Cote, David
    Severgnini, Mariano
    Yearley, Jennifer
    Zhao, Qing
    Blumenschein, Wendy
    Duda, Gabriel
    Muzikansky, Alona
    Jain, Rakesh
    Wen, Patrick
    Reardon, David
    NEURO-ONCOLOGY, 2020, 22 : 138 - 139
  • [43] OUTCOME OF CONTINUATION OF BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA
    Chamberlain, Marc C.
    NEURO-ONCOLOGY, 2011, 13 : 41 - 42
  • [44] Bevacizumab in recurrent glioblastoma: open issues
    Franceschi, Enrico
    Bartolotti, Marco
    Brandes, Alba A.
    FUTURE ONCOLOGY, 2015, 11 (19) : 2655 - 2665
  • [45] Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma
    Jason P. Sheehan
    Georgios Mantziaris
    Adomas Bunevicius
    Journal of Neuro-Oncology, 2024, 167 : 231 - 232
  • [46] Bevacizumab plus irinotecan in recurrent glioblastoma
    Chamberlain, Marc C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 1012 - 1013
  • [47] Irinotecan and bevacizumab in recurrent glioblastoma multiforme
    Jakobsen, Jan Nyrop
    Hasselbalch, Benedikte
    Stockhausen, Marie-Therese
    Lassen, Ulrik
    Poulsen, Hans Skovgaard
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (05) : 825 - 833
  • [48] Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
    Almubarak, Mohammed
    Newton, Michael
    Altaha, Ramin
    JOURNAL OF ONCOLOGY, 2008, 2008
  • [49] Bevacizumab and daily temozolomide for recurrent glioblastoma
    Desjardins, Annick
    Reardon, David A.
    Coan, April
    Marcello, Jennifer
    Herndon, James E., II
    Bailey, Leighann
    Peters, Katherine B.
    Friedman, Henry S.
    Vredenburgh, James J.
    CANCER, 2012, 118 (05) : 1302 - 1312
  • [50] Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma
    Sheehan, Jason P.
    Mantziaris, Georgios
    Bunevicius, Adomas
    JOURNAL OF NEURO-ONCOLOGY, 2024, 167 (01) : 229 - 230
12345